Navigation Links
Neuland Labs Launches Expanded Peptide Manufacturing Capabilities at 22nd American Peptide Symposium
Date:6/22/2011

HYDERABAD, India, June 22, 2011 /PRNewswire/ -- Neuland Laboratories Ltd., a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract research and manufacturing services to customers located in 85 countries, today announced it will unveil its expanded capabilities for synthetic peptide manufacture at the 22nd American Peptide Symposium to be held in San Diego June 25-30, 2011.

"It is fitting that we formally launch our new commercial-scale peptide production service at this important gathering of leading peptide experts from around the world," said M.K. "Mike" Anwer, Ph.D., vice president of research & development at Neuland Labs.  "Neuland's extensive experience in producing a variety of synthetic peptides parallels their increasing use as therapeutics and diagnostics, in antibody production and as research tools.  Our expanded service provides rapid access to commercial quantities of affordable, high quality peptides from a company with a 27-year track record of consistently achieving the highest regulatory standards in global pharmaceutical production."

Neuland Labs offers customers peptide production using standard sequential chemical peptide syntheses and segment condensation strategies.  The company employs solid phase peptide synthesis procedures, as well as solution phase methods for shorter length peptides, and segment condensation and ligation techniques for very long peptides.  Neuland researchers have also developed special methods to economically produce large quantities of high value peptide building blocks such as pseudoproline dipeptides.

Dr. Anwer added, "Our researchers have developed expertise in producing peptides of varying lengths and complexity.  We are especially proud of our success in applying advanced methods for handling the aggregation and purification issues inherent in manufacturing long and complex peptides.  Our diverse peptide customers also benefit from our value-added consultative services in analytical R&D and drug design, process development, optimization, validation, scale-up and the entire regulatory review and approval process.  We work with companies of all sizes and are interested in exploring opportunities for collaborative efforts with a variety of potential partners."

For over 25 years Neuland Labs has been at the forefront of supporting drug development through its consulting services and its cGMP contract and API manufacturing.  Neuland scientists have developed more than 300 processes from bench scale to commercial production and have filed more than 400 drug master files worldwide.  The company has a longstanding record of regulatory excellence, as demonstrated by seven successful FDA inspections since 1997, with the most recent completely free of any Form 483 investigational observations.  Neuland's cGMP certifications also include the TGA, EDQM, German Health Authority, ISO 14001, ISO 27001 and OHSAS 18001.  

"Our new commercial-scale peptide manufacturing service reflects our ongoing strategy to leverage Neuland Labs' innovative scientists, world-class manufacturing expertise, established infrastructure and reputation for quality to expand into new market segments.  At a time when efficiency is critical to business success, we expect that our commitment to cost effectiveness, regulatory rigor and customer service will be a welcome option for peptide researchers and manufacturers," noted Sucheth R. Davuluri, chief executive officer at Neuland Labs.

More information on Neuland's peptide synthesis capabilities is available at Booth #37 at the 22nd American Peptide Symposium, which will be held June 25-30, 2011 at the Sheraton Hotel and Marina in San Diego, California. 

About the American Peptide Society SymposiumEstablished in 1968 by the American Peptide Society, this biannual Symposium assembles national and international peptide scholars, researchers, educators and students together with corporate exhibitors and sponsors. The Symposium brings together investigators of varying backgrounds, with the goal of stimulating discussion, and catalyzing multidisciplinary collaborations in order to push the frontiers of peptide science.  For more information, visit http://www.aps2011.org/

About Neuland Laboratories, Ltd.

For over 25 years Neuland Labs has been at the forefront of supporting drug development through its consulting services and its cGMP contract and API manufacturing.  The company is committed to research, supporting a state-of-the-art R&D operation.  Neuland Labs is listed on India's National Stock Exchange under the symbol NEULANDLAB and on the Bombay Stock Exchange under code 524558.  For more information, visit http://www.NeulandLabs.com Contacts:Neuland Laboratories Limited

US-Neuland Laboratories Inc.

US MediaRavikant Tadinada  

Thomas Speace

BioCom Partners/Brandwidth Solutions+91 9885681385

President & CEO

Barbara LindheimRavikantTadinada@neulandlabs.com

(949) 218-1768

(212) 918-4650TSpeace@neulandlabs.com

blindheim@biocompartners.com
'/>"/>

SOURCE Neuland Laboratories Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Neuland Labs Reports Financial Results for Fiscal Year 2011
2. Transgenomic, Inc. Launches Best-in-Class Next-Generation Sequencing Test for Nuclear Mitochondrial Disorders at the 2011 United Mitochondrial Disease Foundation Meeting
3. Multiple Sclerosis Association of America Launches Mobile Phone App for the Multiple Sclerosis Community
4. Ethicon Endo-Surgery Launches ENSEAL® G2 Super Jaw
5. Lilly for Better Health™ Launches Enhanced Multi-Channel Patient Education Platform
6. Vinomis Laboratories Launches Vindurance Challenge to Substantiate Claims of Enhanced Physical Endurance with Use of Resveratrol and Quercetin
7. MedeAnalytics Launches Value-Based Purchasing Resource Center
8. The Institute for Specialized Medicine Launches GLUTEN-FREE REMEDIES, a New Line of Gluten-free Food Supplements and Herbs.
9. ViroPharma Launches Swell, an Original Documentary Chronicling the Lives of People Living with Hereditary Angioedema
10. Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches
11. Mylan Launches Generic Version of Roxicodone® Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 2016 (Kanadische ... http://www.sedar.com ) und der Website ... --> http://www.sedar.com ) und ... abrufbar.    --> Telesta ... Konzernabschluss des zweiten Quartals und die ...
(Date:2/12/2016)... 2016  Sequent Medical, Inc. gab heute bekannt, ... eine Studie zur Sicherheit und Wirksamkeit des WEB™-Systems ... Behandlung von rupturierten intrakraniellen Aneurysmen begonnen hat. Prof. ... an der Universitätsklinik Bicètre in Paris ... den ersten Patienten aufgenommen. Im Rahmen ...
(Date:2/12/2016)... AUSTIN, Texas , Feb. 12, 2016 ... Institute for Robotic Surgery at St. David,s North Austin ... the da Vinci ® Xi ® Surgical ... ® 7000dV. Thiru Lakshman , M.D., ... performed a total proctocolectomy utilizing Integrated Table Motion technology, ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... 12, 2016 , ... Erlanger Agency has announced a new partnership in its ... campaign focuses on the fight against breast cancer, fundraising for a local woman named ... . , Carmen is a loving single mother of two boys who also serves ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Donor Network West, ... California and Nevada, announced a partnership with San Ramon Regional Medical Center. Under the ... hospital’s facilities as a way to accommodate a more certain time frame for donor ...
(Date:2/12/2016)... ... ... For Coast Dental dentist Everet Lake, DDS, the smiles began at dawn. ... before 7 a.m. to volunteer at Friday’s Dentistry from the Heart event in New ... help hundreds of uninsured and underinsured people receive much-needed dental care. , This ...
(Date:2/12/2016)... ... February 12, 2016 , ... Mediaplanet today announces the ... print component of “Revolutionizing Cancer Care” is distributed within the February 12 issue ... with a circulation of approximately 250,000 copies and an estimated readership of 750,000 ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... Drug Categories: Strategies for Health Plans and PBMs,” an upcoming Feb. 24 webinar ... affordability and access in big-dollar therapeutic categories, such as the $1,000-per-pill hepatitis C ...
Breaking Medicine News(10 mins):